

ACTIVE INGREDIENT: Tiamulin hydrogen fumarate: 10 g/lb

GUARANTEED ANALYSIS

Crude Fat, not less than...... 4% Crude Fiber, not more than...... 50%

Ingredients: rice hulls, mineral oil, porcine gelatin

See reverse side for use directions, cautions and warnings.

Net Weight: 35 lb (15.9 kg)

Do not feed undiluted.

Indications	Amount of Type B Medicated Feed Per Ton of Feed	Tiamulin hydrogen fumarate in Complete Type C Medicated Feed Per Ton	Withdrawal Period (days)
For treatment of swine dysentery associated with <i>Brachyspira</i> (formerly <i>Serpulina</i> or <i>Treponema</i>) hyodysenteriae susceptible to Tiamulin	20 lb	200 g	7
For control of porcine proliferative enteropathies (ileitis) associated with Lawsonia intracellularis	3.5 lb	35 g	2
For control of swine dysentery associated with <i>Brachyspira</i> (formerly <i>Serpulina</i> or <i>Treponema</i>) hyodysenteriae susceptible to Tiamulin	3.5 lb	35 g	2

Warnings:

Observe withdrawal time shown in table above.

Keep out of reach of children. Avoid contact with skin. Direct contact with skin or mucous membranes may cause irritation.

Caution:

Do not feed undiluted. Do not use in feeds for animals other than swine. The effects of tiamulin on swine reproductive performance, pregnancy and lactation have not been determined. Swine being treated with Denagard (tiamulin) should not have access to feeds containing polyether ionophores (e.g., lasalocid, monensin, narasin, salinomycin and semduramicin) as adverse reactions may occur. If signs of toxicity occur, discontinue use.

MIXING DIRECTIONS

Mix this medicated feed (Type B) with non-medicated feed ingredients to make a Type C medicated feed as follows:

Type C Medicated Feed Tiamulin grams/ton Feed		Pounds Non-medicated Feed*
35	3.5	1996.5
200	20	1980

^{*}When making an approved Type C medicated feed drug combination, the inclusion rate of this non-medicated feed should be adjusted for the amount of the other drug added to make such combination Type C medicated feed.

Storage:

Store at or below 25°C (77°F). Temporary excursions to 40°C (104°F) permitted.

To report adverse effects, access medical information, or obtain additional product information call 1-800-428-4441

For a complete listing of adverse reactions for DENAGARD reported to CVM see: www.fda.gov/reportanimalae

Denagard, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates.

Restricted Drug (California): Use only as directed.

Approved by FDA under NADA # 139-472

Marketed by: Elanco US, Inc. Greenfield, IN 46140



